GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol).
Conduit C, Mak B, Qu W, Lulio JD, Burder R, Bressel M, Cusick T, Dhillon HM, Lourenço RA, Underhill C, Torres J, Crumbaker M, Honeyball F, Linton A, Allen R, Davis ID, Clark SJ, Horvath LG, Mahon KL.
Conduit C, et al. Among authors: cusick t.
Ther Adv Med Oncol. 2022 Apr 18;14:17588359221092486. doi: 10.1177/17588359221092486. eCollection 2022.
Ther Adv Med Oncol. 2022.
PMID: 35465297
Free PMC article.